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Abstract: A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal
duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a
correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival
(RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients
treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease
at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced
recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane
discontinuation, to overcome immortal time bias. We found a wide variability in the duration
of adjuvant mitotane treatment among different centers and also among patients cared for at the
same center, reflecting heterogeneous practice. We did not find any survival advantage in patients
treated for longer than 24 months. Moreover, the relationship between treatment duration and the
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frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of
adjuvant treatment. In conclusion, the present findings do not support the concept that extending
adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk
of recurrence.
Keywords: mitotane; adjuvant treatment; adrenocortical cancer; recurrence; recurrence free sur-
vival; timing
1. Introduction
Adrenocortical carcinoma (ACC) is a rare tumor characterized by an aggressive disease
course that limits long-term survival [1–3]. Disease-specific outcomes are better for pa-
tients bearing early-stage tumors that can be resected completely; however, post-operative
recurrence of ACC may be considered as part of the natural history of the disease [4–8].
We have recently reported a recurrence rate of 62.5% among 152 patients with stage I to
III ACC who underwent complete macroscopic resection, with a five-year recurrence-free
survival rate of 38.1% [9].
The remarkable propensity of ACC towards recurrence despite complete surgical
removal makes a strong case for an adjuvant therapy. Until now, the most followed adjuvant
approach relied on mitotane, an old adrenolytic drug specifically approved for treatment of
advanced ACC [10,11]. Use of adjuvant mitotane increased in clinical practice following the
observation that adjuvant mitotane treatment was associated with prolonged recurrence-
free survival (RFS) compared to surveillance without active treatment after surgery, in
a retrospective study of 177 ACC patients managed at different institutions using either
adjuvant mitotane or no treatment. In this cohort study, we included 47 patients followed
at Italian reference centers that systematically adopted adjuvant mitotane to all radically
operated ACC, and a group of 55 Italian patients and 75 German patients followed in
centers not giving any post-operative treatment [12]. In this study, we showed that adjuvant
mitotane treatment was associated with a significant survival advantage. Despite the
retrospective nature of the study, this finding informed clinical practice, although adjuvant
mitotane is not universally accepted and some experts argue against the value of this
approach [13,14]. Critics of adjuvant mitotane therapy evoke the drug-related toxicity,
the complexity of caring for patients on treatment, and the long duration of a treatment
course [15].
The overall level of evidence available on adjuvant mitotane can be graded as low,
and all recommendations are based on retrospective, non-randomized studies, plagued
by potential bias and confounding [10,16]. Despite this evidence gap, adjuvant mitotane
is advised for patients with ACC at high risk of recurrence in the clinical guidelines
endorsed by the European Society for Endocrinology (ESE)–European Network for the
Study of Adrenal Tumours (ENSAT) and by the European Society for Medical Oncology
(ESMO) [10,17]. The guidelines underline that scant information is currently available on
many aspects dealing with practical management of mitotane therapy. Recommendations
on how to conduct adjuvant mitotane treatment are mostly based on expert opinions
stemming from personal experience and practice [18]. As a consequence, care of patients
treated with mitotane is heterogeneous depending on local preferences.
One of the most relevant and uncertain issues concerns the optimal duration of
adjuvant mitotane treatment. The ESE-ENSAT guidelines and ESMO guidelines suggest
continued use of adjuvant mitotane for at least 2 years, but not longer than 5 years [10,17].
Since no study has ever specifically addressed this issue, this recommendation is based on
the observation that most recurrences of ACC occur within two years after resection, while
after 5 years, the rate of recurrence is too low to justify continuation of adjuvant therapy.
What is the optimal duration of adjuvant mitotane treatment, however, remains
controversial, and practice varies even among referral centers. This issue has important
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consequences on both patient-centered outcomes, due to the unwanted effects of treatment
and their impact on quality of life and health-care organizations, as surveillance of patients
on mitotane is demanding and resource-consuming.
We tried to answer this question by organizing an international, multicentric, retro-
spective study aimed at assessing whether a correlation does exist between duration of
adjuvant mitotane treatment and recurrence-free survival of patients with ACC.
2. Patients and Methods
2.1. Patients
We did an international, multicenter, retrospective analysis on 154 patients with ACC
treated with adjuvant mitotane after radical surgery. Thirteen European centers and one
center in Canada participated in the study.
To be included, patients had to meet the following inclusion criteria: age of 18 years
or older at the time of diagnosis; histologically confirmed diagnosis of ACC (based on
Weiss score [19]; ENSAT stage I-III [20]; R0 or Rx tumor resection, defined on the basis of a
surgical report, pathology report, and post-operative imaging); treatment with adjuvant
mitotane for at least 12 months following surgery; and clinical status being free of disease
at the time of mitotane discontinuation. Exclusion criteria were: residual disease after
resection, defined both microscopically or macroscopically (resection status, R1 or R2);
patients concomitantly treated with other therapies (e.g., chemotherapy or radiotherapy);
or patients experiencing ACC recurrence during adjuvant mitotane therapy. Follow-up for
this study was closed in December 2017.
2.2. Methods
All data were obtained by reviewing patient history, medical records, and source docu-
ments. Data were processed by skilled and experienced personnel using specifically tailored
data forms. We reported clinical and demographical characteristics, the date and type of
surgery, stage at diagnosis, pathology reports (Weiss score and Ki-67 index), hormonal status,
date of start and stop of mitotane treatment and reason for stops, date of recurrence and
type of recurrence (single or multiple, local or distant), and the date of last follow-up or
death. Date of diagnosis was defined as the date of surgery. Tumor stage was established
according to the ENSAT classification (I, confined tumors ≤5 cm; II, confined tumors
>5 cm; III, positive lymph nodes or infiltrating neighboring organs/veins without distant
metastases; IV, distant metastases) [20]. Date of recurrence was defined as the date of
radiological evidence of a new lesion. Patients underwent imaging follow-up (abdominal
and thoracic computed tomography) every 3–4 months. Modalities of mitotane treatment,
such as the initial high- or low-dose regimen, dose titration, and eventual dose changes
due to toxicity were done according to local center preferences.
2.3. Statistical Analysis
The primary endpoint was to determine whether a correlation between duration of
adjuvant mitotane treatment and patient survival did exist.
Frequencies and percentages were calculated for categorical data, and the median
and interquartile range for continuous data. Differences in categorical variables were
analyzed by means of the chi-squared test or Fisher test, as appropriate, while differences
in continuous variables were analyzed by the Mann–Whitney U test. The survival curves
were estimated with the Kaplan–Meyer product limit method. Recurrence-free survival
(RFS) was calculated from the time of initial surgery to the first radiological evidence of
recurrence. To adjust for the immortal bias due to the selection of patients who did not
have recurrence on active treatment, we calculated the recurrence-free survival rate after
adjuvant mitotane discontinuation (RFSAM) from the time of discontinuation of mitotane
to ACC recurrence or end of follow-up. We calculated the overall survival rate after
adjuvant mitotane discontinuation (OSAM) from the time of discontinuation of mitotane
to the date of death. Patients who did not experience either of those events (recurrence or
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death) were censored at the date of the last follow-up visit for the specific survival analysis.
Cox proportional hazards regression models were fitted to determine prognostic factors on
survival. The following potential predictive factors for RFS and RFSAM were investigated:
patient sex and age, tumor stage, hormone secretion, Weiss score, Ki67 index, mitoses,
resection status, and duration of mitotane treatment. A genetic algorithm was employed
to select the variables that resulted in the best-fitted model according to AIC score [21].
Firth correction was applied to reduce the bias due to the small number of events [22]. All
reported P values are two-sided. P-values of less than 0.05 were considered as statistically
significant. All statistical analyses were performed using R version 4.0.2.
3. Results
Baseline characteristics of patients are reported in Table 1.
Table 1. Baseline characteristics of patients.
Characteristics Valid Cases (N) Values
Sex, N (%) 154
Male 51 (33%)
Female 103 (67%)
Age at diagnosis, years 154
Median (IQR) 45 (34–54)
Tumor stage at diagnosis, N (%) 154
Stage I 14 (9%)
Stage II 110 (71%)
Stage III 30 (19%)







Tumor size, cm 148
Median (IQR) 10 (7–15)
Ki67 at diagnosis 125
Median (IQR) 10 (5–20)
≤10% 75 (60%)
>10% 50 (40%)
Weiss at diagnosis 132
Median (IQR) 6 (4–6)
Duration of mitotane therapy, months 154
Median (IQR) 33 (24–59)
IQR = interquartile range.
In our series, female sex was more prevalent, and ACC presented, in most cases, as
a stage II hormone-secreting tumor. The present series was skewed toward low-grade
tumors with a Ki67 index of less than 10%. Median duration of adjuvant mitotane therapy
was 33 months (IQR, 24–59), and median follow-up after mitotane discontinuation was
38 months (IQR, 24–61).
We stratified our patients into three groups by treatment duration (expressed in
tertiles); group 1 included patients treated for 13–25 months, group 2 for 26–48 months,
and group 3 for 49–143 months, respectively. Group 3 had a higher Ki67 index, longer RFS
compared to groups 1 and 2, and longer RFSAM compared to group 2 (Table 2).
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Sex, N (%) 0.15
Male 16 (31%) 13 (25%) 22 (43%)
Female 36 (69%) 38 (75%) 29 (57%)
Age at diagnosis, years 0.15
Median (IQR) 47.5 (38.5–58) 45 (32.5–53) 43 (34–51.5)
Tumor stage at diagnosis, N (%) 0.44
Stage I 4 (8%) 5 (10%) 5 (10%)
Stage II 41 (79%) 37 (72%) 32 (63%)
Stage III 7 (13%) 9 (18%) 14 (27%)
Hormone secretion at diagnosis, N (%) 0.41
No 31 (60%) 24 (47%) 29 (57%)
Yes 21 (40%) 27 (53%) 22 (43%)
Size tumor at diagnosis, cm 0.80
Median (IQR) 9.5 (7.2–14.5) 10.5 (7.6–14) 10 (6.7–15.5)
Ki67 at diagnosis 0.014
Median (IQR) 10 (5–10) 10 (5–19) 15 (6–23)
Weiss at diagnosis 0.39
Median (range) 5 (4–6) 6 (4–7) 6 (5–7)
Recurrence, N (%) 0.001
No 47 (90%) 38 (75%) 50 (98%)
Yes 5 (10%) 13 (25%) 1 (2%)
RFS, months <0.001
Median (IQR) 61 (49–97) 59 (48–85) 108 (90–151)
RFSAM, months 0.002
Median (IQR) 38 (26–78) 22 (11–47) 35 (24–62)
OSAM, months 0.19
Median (IQR) 44 (26–78) 37 (22–53) 35 (27–62)
IQR = interquartile range; RFS = recurrence free survival; OSAM = overall survival after adjuvant mitotane discontinuation;
RFSAM = recurrence free survival after adjuvant mitotane discontinuation. Statistically significant differences are presented in bold.
In most cases, mitotane was interrupted at the end of the scheduled period. Only in a
few patients, treatment-related unwanted effects induced mitotane stop (Table 3), mainly
during the second year of therapy.





(Treated for 13–25 Months)
Group 2
n. 51 Patients
(Treated for 26–48 Months)
Group 3
n. 51 Patients
(Treated for 49–143 Months)
End of schedule 30 (57.7%) 38 (74.5%) 47 (92.2%)
Adverse effects 20 (38.5%) 8 (15.7%) 2 (3.9%)
Unattainable target level 0 2 (3.9%) 0
Severe concomitant disease 1 (1.9%) 1 (1.9%) 0
Other * 1 (1.9%) 2 (3.9%) 2 (3.9%)
* patient willing, unexpected pregnancy.
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After excluding patients in which mitotane withdrawal was determined by adverse
effects, we observed a wide variability in the duration of adjuvant mitotane, either among
different centers or in the same center, as shown in Figure 1.
Figure 1. Distribution of the duration of adjuvant mitotane for each center (only centers with at least
five patients have been included in this analysis). 1 = Berlin; 2 = Munich; 3 = Wurzburg; 4 = Florence;
5 = Orbassano; 6 = Padua; 7 = IGR (Villejuif); 8 = Montreal. N = number of patients.
In our series, 19 patients experienced recurrence after mitotane discontinuation. Re-
currence types were almost equally distributed between those which were local (10 cases,
53%) and distant (9 cases, 47%); the last ones mainly in the lung (6 cases). After mitotane
discontinuation, death occurred in three patients, but in only one case the death was
cancer-related.
To assess where any correlation did exist between adjuvant mitotane duration and
RSF, we tried different approaches. We stratified our patients by the value of 24 months’
treatment duration. The comparison of the survival curves of patients treated up to
24 months vs. patients treated for a longer period, both for RFS (Figure 2) and RFSAM
(Figure 3), did not show any significant difference.
Figure 2. Kaplan–Meier estimates of recurrence-free survival (RFS) in patients treated <24 months
versus patients treated >24 months.
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Figure 3. Kaplan–Meier estimates of recurrence free survival after adjuvant mitotane discontinuation
(RFSAM) in patients treated <24 months vs. patients treated >24 months.
We performed univariate analyses, both for RFS (Table 4) and RFSAM (Table 5),
without identifying any significant prognostic factors.
Table 4. Univariate analysis of predictive factors for recurrence-free survival (RFS).
Univariate Analysis Diff HR 95% CI p
Duration of mitotane therapy + 1.302 0.509 3.334 0.58
§ R status 0.722 0.208 2.503 0.61
‡ * Hormone secretion 1.441 0.571 3.640 0.44
* ◦ Stage 0.917 0.272 2.526 0.87
* Tumor size 7.925 0.942 0.514 1.727 0.85
* Weiss 2.000 1.589 0.861 2.932 0.14
* Ki67% 15.000 0.805 0.426 1.521 0.50
* at diagnosis; Reference categories: + patients treated with mitotane ≤27 months, ‡ Secreting tumors, ◦ Stage III,
§ RX.
Table 5. Univariate analysis of predictive factors for recurrence free survival after adjuvant mitotane
discontinuation (RFSAM).
Univariate Analysis Diff HR 95% CI p
Duration of mitotane therapy + 0.894 0.354 2.257 0.812
§ R status 0.843 0.243 2.924 0.788
‡ * Hormone secretion 1.357 0.543 3.391 0.513
* ◦ Stage 1.118 0.342 2.993 0.838
* Tumor size 7.925 0.977 0.532 1.792 0.939
* Weiss 2.000 1.766 0.957 3.260 0.069
* Ki67% 15.000 0.820 0.442 1.521 0.529
* at diagnosis; Reference categories: + patients treated with mitotane ≤27 months, ‡ Secreting tumors, ◦ Stage III,
§ RX.
At a multivariate level, the variables’ duration of adjuvant mitotane, which was
modelled with a spline to account for non-linearity, sex, and Weiss were selected in the
best-fitted model. Duration of adjuvant mitotane was the only statistically significant factor
associated with RFS (HR 0.549, 95% CI 0.306–0.983; p = 0.044). The HR was calculated on a
difference of 18 months in the duration of therapy, that is, 18 months’ increase of adjuvant
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mitotane therapy duration is associated with about 45% reduction in the hazard of RFS.
No statistically significant factor resulted to be associated with RFSAM, or OSAM.
4. Discussion
The present findings do not support the concept that a longer duration of mitotane
therapy (more than 2 years) is associated with a survival advantage. Since the present series
was enriched with low-risk tumors, these results may be not generalizable to high-risk
ACC. Although RFS was prolonged in patients treated for more than 4 years, this finding
may likely be the consequence of immortal time bias.
The inclusion criteria of the study may induce an immortal bias in patients scheduled
to be treated for longer periods, since these patients could not have recurred in the months
prior to mitotane discontinuation, as otherwise they would have been excluded from
analysis. For this reason, we primarily focused on the outcome after the end of scheduled
adjuvant treatment, of whatever duration it was. We calculated the recurrence-free survival
rate after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation,
since landmark analysis is a method used to overcome immortal time bias [23].
The duration of mitotane therapy was a factor associated to RFS but not RFSAM,
and this militates against an actual benefit of prolonging adjuvant mitotane treatment.
Along these lines, the breakdown of RFS by 24 months of treatment duration, which is
the recommended time-length of adjuvant mitotane according to the ESE-ENSAT and
ESMO guidelines [10,17], did not disclose any survival advantage of patients treated
for longer. Moreover, the relationship between treatment duration and the frequency
of ACC recurrence was not linear after stratifying our patients in tertiles of length of
adjuvant treatment.
An interesting finding is that a large variability in the duration of adjuvant mitotane
treatment does appear between different centers, and also among patients cared for at the
same center. This figure reflects uncertainty on management and heterogeneous practice.
However, it appears that physicians were more eager to treat patients with unfavorable
prognostic factors (higher Ki-67 index) for longer periods, although our series was selected
toward low-risk tumors due to the specific inclusion criteria of the study (patients who did
recur on treatment were excluded). That said, a sort of “geographical” pattern does appear,
since at centers in Germany, adjuvant mitotane was generally discontinued after two years,
whereas in Italian centers it was usually more prolonged. In these centers, however, there
was a huge variability between patients, suggesting that a tailored approach, taking into
account patient preferences and biological characteristics of ACC, was followed. The
heterogeneity in practice between expert centers underlines the lack of evidence on this
issue since, to the best of our knowledge, this is the first study that specifically addresses
the issue of the duration of adjuvant mitotane therapy. As a matter of fact, duration of
adjuvant mitotane was very heterogenous between studies on this topic [14,24–28].
The main issue with a retrospective analysis of treatment duration is that in many
cases, the length of adjuvant treatment is set by the timing of ACC recurrence, and not
by the planned treatment schedule. In this retrospective multicenter study carried out in
referral centers for ACC that are part of ENSAT, we tried to overcome this problem by
including only patients treated with adjuvant mitotane for at least 12 months, in which
mitotane was suspended for reasons different from recurrence of disease. Consequently,
all patients were free of disease at the end of adjuvant therapy.
Recognizing that a prospective randomized trial that includes patients with ACC
treated with adjuvant mitotane for different, pre-specified time lengths is the best way to
define what is the optimal duration of treatment, it can be plainly accepted that such a
trial is not on the horizon for the near future. Up to now, only two randomized trials have
been concluded on ACC [29,30], and this outlines how it is challenging to implement a
randomized trial in a rare tumor such as ACC. Therefore, a well-designed retrospective
study is almost all that can be done to answer this important clinical question.
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5. Conclusions
In this study, we have addressed the challenging issue of identifying the optimal
duration of adjuvant mitotane therapy in a retrospective analysis. We tried to overcome
the bias and confounding inherent to a retrospective analysis of treatment duration by
multiple approaches. With all the disclosed limits of our study, the present findings do
not support the concept that extending adjuvant mitotane treatment over two years is
beneficial for patients with ACC at low risk of recurrence. Conversely, patients with
ACC at high risk of recurrence were under-represented in this study, thus precluding any
definitive recommendations.
Answering the question of what is the optimal duration of adjuvant mitotane is an
unmet clinical need, since current practice is heterogeneous and mainly dependent on
personal preferences and expertise. To the best of our knowledge, no previous study
has specifically addressed this point, and the recommendation of a standard duration
of adjuvant mitotane treatment of two years is not based on specific evidence. Lacking
randomized studies, which will be hardly feasible in the future, the present study does
provide the only evidence available on this complex issue. Finding that no obvious
advantage is associated to prolonged adjuvant mitotane treatment provides some guidance
for the care of patients with ACC, and sparing low-risk patients from long exposure to a
toxic treatment matters for clinical practice.
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